CCL2 Promotes Novel Coronavirus-Mediated Inflammatory Responses in Macrophages.


Journal

Clinical and investigative medicine. Medecine clinique et experimentale
ISSN: 1488-2353
Titre abrégé: Clin Invest Med
Pays: Canada
ID NLM: 7804071

Informations de publication

Date de publication:
28 09 2023
Historique:
received: 07 02 2023
accepted: 07 02 2023
medline: 23 10 2023
pubmed: 29 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

The hyperinflammatory response is one of the main complications associated with novel coronavirus disease 2019 (COVID-19), and there is no effective treatment for cytokine storm. Therefore, it is important to investigate the key genes associated with severity of the disease. In this study, we used a microarray data set to analyze the key genes associated with severe illness in patients with COVID-19. The proportion of immune cells was determined using the CIBERSORT algorithm. The key genes were further verified by detecting the levels of cytokines and chemokines in the serum of patients. Additionally, macrophages were stimulated with SARS-CoV-2 spike protein and chemokine ligand (CCL) 2. The expression of cytokines, ERK1/2, and NF-κB in macrophages was detected. Four hub genes were identified. Among them, C-C motif chemokine receptor 2 (CCR2) was an upregulated hub gene, while killer cell lectin-like receptor subfamily K member 1 (KLRK1), macrophage colony-stimulating factor receptor (CSF1R), and CD3D human recombinant protein (CD3D) were downregulated genes. Immune cell type identification found that the proportion of monocytes was higher in patients with severe COVID-19 than that in controls. Moreover, levels of CCL2 were significantly higher in patients with COVID-19. When stimulated with SARS-CoV-2 S protein and CCL2, macrophages secreted more inflammatory cytokines. The expression level of ERK1/2 was elevated. These results suggested that S protein and CCL2 may mediate macrophage inflammatory responses through the ERK1/2 signaling pathway. This study provides a basis for clinical treatment and improves the prognosis of critically ill patients with COVID-19.

Identifiants

pubmed: 37769276
doi: 10.25011/cim.v46i3.40273
doi:

Substances chimiques

spike protein, SARS-CoV-2 0
Cytokines 0
Chemokines 0
CCL2 protein, human 0
Chemokine CCL2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E34-45

Auteurs

Fang Ding (F)

Clinical Research Center, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China; Taizhou Center for Disease Control and Prevention, 225300, Taizhou, China.

Muwei Dai (M)

The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Orthopaedic Department, 050011, Shijiazhuang, China.

Xichun Kang (X)

Clinical Research Center, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China.

Xin Zhang (X)

Clinical Research Center, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China.

Li Li (L)

Department of Critical Care Medicine, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China.

Lei Zhao (L)

Department of Critical Care Medicine, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China.

Ping Jiang (P)

Department of Critical Care Medicine, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China.

Huixia Gao (H)

Clinical Research Center, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China.

Huimin Yan (H)

Clinical Research Center, Shijiazhuang Fifth Hospital, 050021, Shijiazhuang, China. yanhm2538@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH